Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

233.37 -2.13 (-0.90%)
Official Closing Price Updated: 4:10 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Penumbra (PEN) Shares Are Falling Today
Shares of medical device company Penumbra (NYSE:PEN) fell 5.5% in the afternoon session after the company announced results from its landmark STORM-PE randomized controlled trial. The study found that... 
Via StockStory
Topics Artificial Intelligence
Deep Dive Into Penumbra Stock: Analyst Perspectives (13 Ratings)
 
Via Benzinga
Can Penumbra's 'Landmark' Study Vs. Blood Thinners Change Guidelines?
Penumbra pitted its device, Lightning Flash, with blood thinners vs. blood thinners, alone, in patients with pulmonary embolism. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Penumbra Stock In The Last 10 Years
 
Via Benzinga
A Look Into Penumbra Inc's Price Over Earnings
 
Via Benzinga
Peering Into Penumbra Inc's Recent Short Interest
 
Via Benzinga
What Does the Market Think About Penumbra?
 
Via Benzinga
Penumbra (PEN) Stock Trades Up, Here Is Why
Shares of medical device company Penumbra (NYSE:PEN) jumped 3.2% in the morning session after Needham upgraded the stock to 'Buy' from 'Hold' and set a price target of $326. 
Via StockStory
Topics World Trade
This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
 
Via Benzinga
9 Analysts Assess Penumbra: What You Need To Know
 
Via Benzinga
3 Low-Volatility Stocks We Approach with Caution
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Topics Economy
$100 Invested In Penumbra 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Expert Outlook: Penumbra Through The Eyes Of 7 Analysts
 
Via Benzinga
Merit Medical Systems, ICU Medical, and Penumbra Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential... 
Via StockStory
Topics World Trade
Here's How Much $100 Invested In Penumbra 10 Years Ago Would Be Worth Today
 
Via Benzinga
1 High-Flying Stock to Own for Decades and 2 We Turn Down
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
Oscar Health, Penumbra, DexCom, Merit Medical Systems, and HCA Healthcare Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. 
Via StockStory
Topics Economy
3 Healthcare Stocks We’re Skeptical Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
3 Mid-Cap Stocks We Steer Clear Of
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Deep Dive Into Penumbra Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
This Penumbra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q2
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - cardiology,... 
Via StockStory
3 Cash-Heavy Stocks We Keep Off Our Radar
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
PEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance
Medical device company Penumbra (NYSE:PEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.4% year on year to $339.5 million. The company’s full-year revenue... 
Via StockStory
1 Safe-and-Steady Stock with Promising Prospects and 2 We Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Penumbra PEN Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
3 Cash-Producing Stocks Walking a Fine Line
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.